Genetic biomarker trumps tissue type in landmark oncology approval

Nature Reviews Drug Discovery 16, 447 (2017). doi:10.1038/nrd.2017.128 Author: Asher Mullard The FDA granted accelerated approval to Merck & Co.'s PD1 blocker pembrolizumab for all cancers with a specific genetic biomarker, regardless of which tissue type is involved. “This is an important first for the cancer community,” said the FDA's Richard Pazdur, acting director of the
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research